GleamWall
中文EN

LNSR LENSAR, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1320350 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY29.3%
TTM net income YoY-292.7%
TTM EPS YoY-289.8%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—

Margins

Gross margin47.2%
Operating margin-25.0%
Net margin-84.5%
FCF margin-9.0%
EBITDA margin-19.3%

Returns

ROE-16,631.7%
ROA-74.8%
ROIC (approx.)—
Asset turnover0.89x

Leverage & solvency

Liabilities / assets113.2%
Debt / equity—
Current ratio1.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-67.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$14.13M$16.50M$13.43M$16.02M$14.32M$13.94M$14.16M$16.73M
Cost of revenue$5.97M$6.72M$7.05M$9.09M$8.28M$6.91M$7.03M$9.62M
Gross profit$8.16M$9.78M$6.38M$6.94M$6.04M$7.02M$7.12M$7.11M
R&D expense$1.31M$1.27M$1.39M$1.30M$1.37M$1.43M$1.53M$1.33M
SG&A expense$8.06M$6.14M$2.53M$10.33M$12.02M$11.66M$11.15M$6.83M
Operating income-$1.43M$2.13M$2.24M-$4.92M-$7.58M-$6.29M-$5.79M-$1.29M
Income tax$0$0$0—$0$0$0—
Net income-$4.72M$3.54M$36.33M-$1.46M-$3.71M-$1.76M-$27.34M-$18.70M
EBITDA-$590,000$3.01M$3.14M-$3.98M-$6.65M-$5.42M-$4.95M-$416,000
EPS (basic)-0.380.141.56—-0.31-0.15-2.32—
EPS (diluted)-0.380.100.00—-0.31-0.15-2.32—
Weighted avg. shares (diluted)12.40M23.03M15.42M—12.04M11.94M11.77M—
Balance sheet
Cash & equivalents$12.62M$13.56M$12.49M$12.97M$7.64M$7.15M$19.55M$16.26M
Short-term investments$0$0$1.00M$5.00M$9.23M$13.16M$5.70M$6.19M
Receivables$5.14M$6.17M$4.90M$6.38M$5.90M$4.99M$6.88M$6.08M
Inventory$25.14M$24.87M$23.10M$21.52M$20.60M$19.24M$15.32M$11.43M
Current assets$44.49M$47.03M$42.40M$46.77M$44.43M$45.87M$49.19M$41.98M
PP&E, net$524,000$445,000$457,000$505,000$555,000$609,000$577,000$664,000
Intangibles$4.51M$4.73M$4.96M$5.19M$5.42M$5.65M$5.88M$6.11M
Total assets$67.07M$69.56M$66.22M$71.43M$70.20M$70.41M$72.96M$66.30M
Current liabilities$19.81M$19.64M$17.80M$40.57M$35.73M$30.09M$27.17M$15.00M
Total liabilities$42.22M$40.87M$41.65M$83.67M$82.33M$79.68M$81.32M$47.65M
Shareholders' equity$11.07M$14.90M$10.79M-$26.02M-$25.91M-$23.05M-$22.14M$4.86M
Shares outstanding12.29M12.28M12.10M11.99M11.94M11.93M11.79M11.65M
Cash flow statement
Operating cash flow-$866,000-$127,000-$4.27M$618,000-$3.51M-$5.00M-$6.94M$3.66M
Capital expenditure$112,000——$0$0$77,000$6,000$3,000
Free cash flow-$978,000——$618,000-$3.51M-$5.08M-$6.94M$3.65M
Investing cash flow-$112,000$965,000$4.00M$4.25M$4.00M-$7.49M$531,000$1.99M
Financing cash flow$35,000$233,000-$209,000$474,000$0$93,000$9.69M$172,000
Depreciation & amortization$843,000$878,000$904,000$944,000$928,000$865,000$844,000$874,000
Stock-based compensation$850,000$347,000$690,000$873,000$850,000$766,000$654,000$662,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.